This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.

Consumer Law
Consumer Protection
Deceptive Advertising

In the Matter of POM Wonderful LLC and Roll Global LLC, as successor in interest to Roll International Corporation, companies, and Stewart A. Resnick, Lynda Rae Resnick, and Matthew Tupper, individually and as officers of the companies

Published: Jul. 7, 2012 | Result Date: May 22, 2012 | Filing Date: Jan. 1, 1900 |

Case number: 9344 Bench Decision –  Defendants ordered to cease false advertising

Court

Federal Trade Commission


Attorneys

Claimant

Devin W. Domond
(Federal Trade Commission)

Janet M. Evans
(Federal Trade Commission)

Mary K. Engle

Michael F. Ostheimer
(Federal Trade Commmission)

Elizabeth K. Nach

Serena Viswanathan

Heather Hippsley

Mary L. Johnson

Tawana E. Davis
(Federal Trade Commission)

Elise D. Whang

Andrew D. Wone
(Federal Trade Commission)


Respondent

Kristina M. Diaz
(Roll Law Group PC)

Skye L. Perryman

Bertram H. Fields

John D. Graubert
(Covington & Burling LLP)


Facts

The Federal Trade Commission initiated a complaint against Respondents, alleging that the advertised health benefits of the respondents' pomegranate juice products were false because they were not based upon scientific research involving comparative control groups and placebos.

Result

The decision found 12 of respondents' ads implied health benefits not supported by Respondents' scientific studies. The complaint was upheld and Hon. Michael Chappell recommended an order requiring that all health claims made by respondents have adequate substantiation. Respondents would not be held to the same strict standards as pharmaceutical companies, but rather would merely have to demonstrate that their claims were based on "competent reliable scientific evidence."


#111413

For reprint rights or to order a copy of your photo:

Email jeremy@reprintpros.com for prices.
Direct dial: 949-702-5390